Workflow
销售毛利率
icon
Search documents
澳洋健康收盘上涨1.23%,滚动市盈率111.12倍,总市值31.47亿元
Sou Hu Cai Jing· 2025-08-01 08:43
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aoyang Health, indicating a significant decline in revenue and profit in the latest quarterly report, alongside a high PE ratio compared to industry averages [1][2] Group 2 - On August 1, Aoyang Health's closing price was 4.11 yuan, with a 1.23% increase, and a rolling PE ratio of 111.12, marking a new low in 33 days, with a total market value of 3.147 billion yuan [1] - The average PE ratio for the healthcare service industry is 47.90, with a median of 59.27, placing Aoyang Health at the 39th position in the industry ranking [1] - For the first quarter of 2025, Aoyang Health reported a revenue of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82%, with a sales gross margin of 15.09% [2] - Aoyang Health's main business includes medical services, pharmaceutical distribution, and biotechnology, with key products being medical services and pharmaceutical logistics [1] - The company has received several honors, including being ranked 32nd in the non-public hospital top 100 list and second among county-level non-public hospitals in China [1]
中国石化收盘上涨1.86%,滚动市盈率16.10倍,总市值7286.84亿元
Sou Hu Cai Jing· 2025-07-30 10:48
Group 1 - The core viewpoint of the articles highlights that Sinopec's stock closed at 6.01 yuan, with a PE ratio of 16.10 times, and a total market capitalization of 728.68 billion yuan [1] - Sinopec ranks 11th in the oil industry based on PE ratio, with the industry average at 13.24 times and the median at 31.00 times [1] - As of the first quarter of 2025, 77 institutions hold shares in Sinopec, with a total holding of 16.77 million shares valued at 946 million yuan [1] Group 2 - Sinopec's main business includes oil and gas exploration, development, production, and refining, as well as chemical manufacturing and marketing [1] - The latest financial results for the first quarter of 2025 show revenue of 735.36 billion yuan, a year-on-year decrease of 6.91%, and a net profit of 13.26 billion yuan, down 27.60% year-on-year, with a gross profit margin of 15.66% [1] - The PE ratio of Sinopec is compared to other companies in the industry, with the average PE at 13.24 times and the median at 31.00 times, indicating a competitive position within the sector [2]
南京商旅收盘下跌1.15%,滚动市盈率118.79倍,总市值37.49亿元
Sou Hu Cai Jing· 2025-07-29 10:13
Company Overview - Nanjing Commercial Travel Co., Ltd. focuses on commercial trade and tourism, with main products including textiles, machinery, chemical raw materials, metal materials, non-metallic minerals, tourism services, and general retail [1] - As of March 31, 2025, the company had 30,086 shareholders, a decrease of 906 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Financial Performance - For Q1 2025, the company reported revenue of 191 million yuan, a year-on-year decrease of 7.98%, and a net profit of 3.51 million yuan, down 80.03% year-on-year, with a gross profit margin of 22.30% [1] - The current stock price is 12.07 yuan, down 1.15%, with a rolling PE ratio of 118.79 times, and a total market capitalization of 3.749 billion yuan [1] Industry Comparison - The average PE ratio for the trade industry is 47.62 times, with a median of 38.89 times, positioning Nanjing Commercial Travel at the 33rd rank within the industry [1][2] - The industry average market capitalization is 9.521 billion yuan, while the median is 7.918 billion yuan [2]
东富龙收盘下跌1.26%,滚动市盈率72.05倍,总市值107.75亿元
Sou Hu Cai Jing· 2025-07-28 09:13
Group 1 - The core business of the company is to provide pharmaceutical companies worldwide with pharmaceutical processes, core equipment, and overall system engineering solutions [1] - The company's main products include bioprocessing, formulation, engineering solutions, and food equipment engineering [1] - As of the first quarter of 2025, the company reported revenue of 1.137 billion yuan, a year-on-year increase of 2.58%, and a net profit of 20.1326 million yuan, a year-on-year decrease of 68.87% [1] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 72.05, significantly higher than the industry average of 55.28 and the industry median of 38.06 [2] - The total market capitalization of the company is 10.775 billion yuan [2] - As of the first quarter of 2025, there is only one institutional holder of the company, with a total holding of 2.1845 million shares valued at 2.9 million yuan [1]
麦克奥迪收盘上涨1.02%,滚动市盈率50.00倍,总市值82.27亿元
Sou Hu Cai Jing· 2025-07-11 09:13
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of MacAudie, with a current stock price of 15.9 yuan and a PE ratio of 50.00 times, indicating a higher valuation compared to the industry average [1][2] - As of the first quarter of 2025, MacAudie reported a revenue of 316 million yuan, representing a year-on-year increase of 5.91%, and a net profit of 34.88 million yuan, with a year-on-year growth of 9.70% [1] - The company's main business includes the production and sales of epoxy insulation components, optical microscopes, molds, and medical testing products, along with medical diagnostic services and energy internet technology research and operation [1] Group 2 - In terms of market capitalization, MacAudie has a total market value of 8.227 billion yuan, ranking 103rd in the electric grid equipment industry, which has an average PE ratio of 37.07 times and a median of 39.07 times [1][2] - The latest data shows that eight institutions hold shares in MacAudie, with a total holding of approximately 336.88 million shares valued at 5.596 billion yuan [1] - The sales gross margin for MacAudie stands at 41.77%, indicating a healthy profitability level within its operational framework [1]
ST景峰收盘下跌1.34%,滚动市盈率36.49倍,总市值51.64亿元
Sou Hu Cai Jing· 2025-07-03 08:27
Company Overview - Hunan Jingfeng Pharmaceutical Co., Ltd. specializes in the research, manufacturing, and sales of pharmaceutical products, with a diverse product line including unique national insurance drugs [2] Financial Performance - For Q1 2025, the company reported revenue of 100 million yuan, a year-on-year decrease of 0.46%, and a net loss of approximately 11.9 million yuan, a significant decline of 960.04% compared to the previous year [3] - The gross profit margin for the company stands at 66.62% [3] Market Position - As of July 3, 2023, the company's stock closed at 5.87 yuan, down 1.34%, with a rolling price-to-earnings (PE) ratio of 36.49 times, compared to the industry average PE of 54.72 times and a median of 33.17 times, placing the company at the 95th position in the industry [1][3] - The total market capitalization of the company is 5.164 billion yuan [1] Shareholding Structure - As of the Q1 2025 report, two institutions hold shares in the company, with a total of 12,476.40 million shares valued at 558 million yuan [1]
岳阳兴长收盘下跌1.34%,滚动市盈率103.53倍,总市值57.08亿元
Sou Hu Cai Jing· 2025-07-01 08:28
Company Overview - Yueyang Xingchang's closing price on July 1 was 15.44 yuan, down 1.34%, with a rolling PE ratio of 103.53 times and a total market value of 5.708 billion yuan [1] - The company operates in the petrochemical sector, focusing on the development, production, and sales of chemical new materials, energy conservation and environmental protection, and energy chemical products [1] - Main products include methyl tert-butyl ether, liquefied petroleum gas, propylene, industrial isooctane, ortho-cresol, calcined petroleum coke, and special polypropylene [1] Financial Performance - For Q1 2025, the company reported operating revenue of 1.063 billion yuan, a year-on-year increase of 27.85% [1] - Net profit for the same period was 13.6081 million yuan, reflecting a year-on-year decrease of 37.00% [1] - The sales gross margin stood at 18.85% [1] Shareholder Information - As of March 31, 2025, the number of shareholders was 22,331, an increase of 408 from the previous count [1] - The average market value of shares held per shareholder was 352,800 yuan, with an average holding of 27,600 shares [1] Industry Comparison - The average PE ratio for the petrochemical industry is 12.81 times, with a median of 29.80 times, positioning Yueyang Xingchang at 19th place within the industry [2] - The company's PE ratio is significantly higher than the industry average, indicating potential overvaluation compared to peers [2]
北部湾港收盘下跌1.37%,滚动市盈率19.67倍,总市值201.44亿元
Jin Rong Jie· 2025-06-12 08:25
Group 1 - The closing price of Beibu Gulf Port is 8.66 yuan, down 1.37%, with a rolling PE ratio of 19.67 times and a total market value of 20.144 billion yuan [1] - The average PE ratio for the shipping and port industry is 14.02 times, with a median of 14.63 times, placing Beibu Gulf Port at the 25th position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Beibu Gulf Port is 37,861, a decrease of 3,810 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Beibu Gulf Port Co., Ltd. specializes in container and bulk cargo handling, storage, port value-added services, and supporting port services [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 1.643 billion yuan, a year-on-year increase of 6.73%, and a net profit of 196 million yuan, a year-on-year decrease of 49.87%, with a gross profit margin of 29.74% [1]
超研股份收盘上涨1.28%,滚动市盈率70.66倍,总市值111.84亿元
Sou Hu Cai Jing· 2025-06-09 10:14
Group 1 - The core viewpoint of the news is that Chao Yan Co., Ltd. has a high rolling price-to-earnings (PE) ratio of 70.66, significantly above the industry average of 50.64, indicating a premium valuation in the medical device sector [1][2] - As of June 9, the company's stock closed at 26.11 yuan, with a market capitalization of 11.184 billion yuan, reflecting a 1.28% increase [1] - The company has experienced a net outflow of main funds amounting to 245.27 million yuan on June 9, with a total outflow of 2,328.49 million yuan over the past five days [1] Group 2 - Chao Yan Co., Ltd. specializes in the research, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with key products including industrial ultrasound, medical ultrasound, and X-ray equipment [1] - The company has established a strong market presence and customer base, with its industrial ultrasound non-destructive testing products recognized as a Guangdong Province brand product [1] - In 2022, the company received a second-class award for national defense technology invention from the Ministry of Industry and Information Technology for its project on "New Technology for High-Precision Non-Destructive Testing of Complex Large Components and Its Major Applications" [1] Group 3 - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 98.4324 million yuan, representing a year-on-year increase of 28.69%, and a net profit of 39.3220 million yuan, up 47.70% year-on-year, with a gross profit margin of 73.83% [1]
新开源收盘上涨2.77%,滚动市盈率27.99倍,总市值86.42亿元
Sou Hu Cai Jing· 2025-06-09 09:19
Company Overview - The company, Boai New Kaineng Medical Technology Group Co., Ltd., specializes in fine chemicals and precision medicine, with key products including PVPK30, PVP-I, PVP series, and early cancer diagnosis services [1] - The latest financial report indicates that for Q1 2025, the company achieved a revenue of 325 million yuan, a year-on-year decrease of 17.69%, and a net profit of 80.42 million yuan, down 33.75%, with a gross profit margin of 44.07% [1] Market Performance - As of June 9, the company's stock closed at 17.83 yuan, reflecting an increase of 2.77%, with a rolling price-to-earnings (PE) ratio of 27.99, marking a new low in 48 days [1] - The total market capitalization of the company is 8.642 billion yuan [1] - In terms of capital flow, on June 9, the company saw a net inflow of 3.2614 million yuan, with a total inflow of 10.0675 million yuan over the past five days [1] Industry Comparison - The average PE ratio for the chemical products industry is 43.87, with a median of 39.46, positioning the company at 81st in the industry ranking [2] - The company's static PE is 24.71, and its price-to-book ratio is 2.33 [2]